SCHEDULE: Cheever III Discloses 13.1% Stake in CV Sciences

Charles E. Cheever III has reported beneficial ownership of 26,648,711 shares, representing 13.1% of CV Sciences, Inc. common stock, as of November 24, 2024.

Summary

• Charles E. Cheever III has filed a Schedule 13G, indicating a significant passive investment in CV Sciences, Inc.
• The filing reports beneficial ownership of 26,648,711 shares of common stock.
• This ownership stake represents 13.1% of the total outstanding common stock of CV Sciences, Inc.
• The reporting person has sole voting and sole dispositive power over these shares.
• The filing clarifies that 881,700 shares are held in a trust where Cheever III acts as trustee, with no personal pecuniary interest.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant passive investment stake without immediate implications for control or strategy.

Positives

• Significant investor confidence indicated by a substantial stake (13.1%) in CV Sciences, Inc.
• Clear disclosure of ownership provides transparency to the market.
• The investor has sole voting and dispositive power, suggesting conviction in their investment.

Negatives

• The filing does not provide details on the investment strategy or future intentions beyond passive ownership.
• The inclusion of trust shares, while disclosed, adds a layer of complexity to direct individual control.

Risks

• Potential for future changes in beneficial ownership that could impact share price.
• The passive nature of the investment means it's not directly contributing to company strategy or governance improvements.

Future Outlook

The filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders who acquire more than 5% of a company's stock. This filing indicates a substantial passive stake in the cannabis-related consumer products sector, where CV Sciences operates.

Stakeholder Impact

• Shareholders: Increased transparency regarding a major shareholder's stake, potentially influencing market perception.
• Company Management: May face increased scrutiny or engagement from a significant passive investor.

Next Steps

• Continued monitoring of CV Sciences, Inc. for any strategic shifts or further disclosures from significant shareholders.

Key Dates

Keywords

CV Sciences, Schedule 13G, Beneficial Ownership, Common Stock, Investment Stake, Passive Investment, Shareholder